888-451-4321Lenoir, NC November 2, 2020 – Exela is pleased to announce that it has divested its ownership of the NDA 212535, covering L-Cysteine Hydrochloride Injection. This NDA was acquired from Avadel Legacy Pharmaceuticals as part of a four products transaction which closed on July 1, 2020. The divestiture includes a license that allows the new owner to enter the market well before the expiry of Exela’s several patents, after obtaining any necessary approvals. “We are pleased to have completed this transaction quickly and efficiently with a competent and reputable injectable products manufacturer/marketer that will commercialize the L-Cysteine Injection product,” stated Dr. Phanesh Koneru, President & CEO of Exela. For clarification, Exela continues to own and market its ELCYS® brand of L-Cysteine Hydrochloride Injection under NDA 210660.
About Exela Pharma Sciences
Exela Pharma Sciences, a fast-growing US based integrated specialty pharmaceutical company, focuses on developing, manufacturing and marketing proprietary and generic sterile injectable products with the healthcare provider and patient in mind. Our goal is to deliver high quality, affordable products that make a difference in people’s lives and meet the needs of the healthcare providers that treat them. Built from a strong Research and Development, Regulatory and Quality foundation, Exela is focused on delivering excellence in Quality, Reliability and Affordability. Established in 2005 by a former Pharmacist, Exela receives awards for its supply chain commitment and dedication to creating hundreds of high value jobs in rural America. All of Exela’s development and manufacturing operations are in Lenoir, North Carolina. Please visit www.exelapharma.com to learn more.
For more information, contact Mark Hartman at mhartman@exela.us